Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0032463 (
polycythemia vera
)
3,374
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Analysis of the human androgen receptor gene (
HUMARA
) allows clonality to be assessed in essential thrombocythemia (ET) and
polycythemia vera
(PV). We studied clonality in 44 patients with ET, 18 with PV and in 64 healthy controls. The X-chromosome inactivation pattern was analyzed by
HUMARA
-polymerase chain reaction on DNA from purified granulocytes, T lymphocytes and the CD3- fraction of mononuclear cells.
...
PMID:Clonality analysis by HUMARA assay in Spanish females with essential thrombocythemia and polycythemia vera. 1571 May 83
The JAK2V617F mutation is present in most patients with
polycythemia vera
(PV) and in some patients with essential thrombocythemia (ET) and myeloid metaplasia/myelofibrosis (MMM). We sought to investigate the relationship between granulocyte clonality and JAK2V617F allelic ratio. A total of 168 of 190 female patients were informative for a clonality assay at the
HUMARA
locus; 80% of MMM, 75% of PV, and 67% of ET patients demonstrated clonal granulopoiesis. The JAK2V617F allele was detected by quantitative real-time polymerase chain reaction (PCR) in 99% of PV, 72% of ET, and 39% of MMM. A correlation between clonality and JAK2V617F allelic ratio was demonstrated for PV (P < .001) but not for ET or MMM (both P > .6). These data suggest that acquisition of the JAK2V617F mutation may be sufficient for the development of PV, but additional genetic events are necessary in ET and MMM. In addition, some ET and MMM patients with clonal granulopoiesis have somatic mutations other than JAK2V617F.
...
PMID:X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. 1643 90